(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 January 2023 (12.01.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/283441 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 31/00* (2006.01)

(21) International Application Number:
PCT/US2022/036548

(22) International Filing Date:
08 July 2022 (08.07.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/220,362 09 July 2021 (09.07.2021) US
63/282,356 23 November 2021 (23.11.2021) US

(71) Applicant: **ASTRAZENECA PHARMACEUTICALS LP** [US/US]; 1800 Concord Pike, Wilmington, DE 19850 (US).

(72) Inventors: **JOSHI, Vidya**; 121 Oyster Point Blvd, South San Francisco, CA 94080 (US). **ARCHBELL, James**; 121 Oyster Point Blvd, South San Francisco, CA 94080 (US). **LACHACZ, Kellisa**; 121 Oyster Point Blvd, South San Francisco, CA 94080 (US). **LAMPA, Charina**; 121 Oyster Point Blvd, South San Francisco, CA 94080 (US). **MELLO, Lauren**; 4222 Emperor Blvd, Suite 250, Durham, NC 27703 (US). **GUTIERREZ, Gertrude**; 121 Oyster Point Blvd, South San Francisco, CA 94080 (US). **LECHUGA-BALLESTEROS, David**; 121 Oyster Point Blvd, South San Francisco, CA 94080 (US). **TAN, Penny**; 121 Oyster Point Blvd, South San Francisco, CA 94080 (US). **RIEBE, Michael**; 121 Oyster Point Blvd, South San Francisco, CA 94080 (US).

(74) Agent: **CHEEMA, Sangeeta, K.** et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, WA 98104-7064 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,

(54) Title: COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY




FIG. 29

(57) Abstract: Compositions, methods, and systems are provided for pulmonary delivery of active agents via a metered dose inhaler. In some embodiments, the compositions comprise an HFO-1234ze(E) suspension medium, active agent particles, and suspending particles. The active agent particles may comprise one, two, three or four active agent(s) selected from a long-acting muscarinic antagonist (LAMA), a long-acting β2-agonists (LABA), a short-acting beta-agonists (SABA), an inhaled corticosteroid (ICS), and a non-corticosteroid anti-inflammatory agent.

WO 2023/283441 A1

[Continued on next page]

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*